Colorectal cancer cetuximab monoclonal antibody anti-drug trace amount DNA mutation detection method and device

Abstract

The invention discloses a colorectal cancer cetuximab monoclonal antibody anti-drug trace amount DNA mutation detection method and a colorectal cancer cetuximab monoclonal antibody anti-drug trace amount DNA mutation detection device. The method comprises the following steps: extracting free DNA from a sample; constructing a library by using the free DNA; enriching the library; capturing the enriched library by using a capture probe to obtain captured DNA; sequencing the captured DNA to obtain the sequencing result; and comparing the sequencing result with a reference sequence and detecting amutation site. By the method, low-initial-quantity DNA enriched capture sequencing mutation detection is realized.

Description

technical field [0001] The invention belongs to the field of biotechnology, in particular to cancer gene detection. More specifically, the invention relates to a method and device for colorectal cancer cetuximab drug-resistant trace DNA enrichment capture sequencing mutation detection. Background technique [0002] Colorectal cancer is the most common gastrointestinal tumor worldwide. According to the statistics of authoritative organizations, there are more than 1,400,000 new cases and nearly 700,000 deaths every year in the world, ranking the forefront of all malignant tumors in terms of morbidity and mortality [1]. In the United States, with the continuous popularization of early screening and the continuous improvement of perioperative treatment methods, the 5-year survival rate of localized and regional colorectal cancer has reached more than 70%, but the 5-year survival rate of metastatic colorectal cancer The survival rate is still about 13%-14%, suggesting that the ...

AI Technical Summary

Problems solved by technology

These methods have the following limitations: (1) the detection results of surgical tissue detection in patients with recurrence and metastasis are inaccurate

Temporal heterogeneity caused by tumor evolution can lead to false negative results for some samples

At the same time, there is genomic heterogeneity at the spatial level within the tumor and among metastatic lesions in different parts, and the sampling offset of tissue biopsy will also affect the accuracy of detection results

(2) The tissue biopsy may cause the metastasis of cancer cells, which has a certain clinical risk; (3) The detection range of genes is small

(4) The sensitivity of fluorescent quantitative PCR or Sanger detection platform is limited, and low-abundance gene mutations cannot be accurately detected

Images